MASS
VENTE TOTALE: 244 435 titres (~2 398 472,03 $ US)
- Insiders
- Brown Christopher D., Knopp Kevin J.
- Total bought
- —
- Total sold
- $2,398,472
- Last activity
- 2026-09-02
- Last synced
-
2026-09-08 09:54:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-08
MASS presents a mixed profile: a moderate earnings catalyst (23% YoY revenue growth, raised 2026 outlook, BlackRock entry) is partially offset by structurally weak fundamentals marked by persistent cash burn and…
The first sentence of the analysis written for MASS on 2026-09-08 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 47.7% | 50.2% | 50.4% | 55.5% | 55.0% | |
| Ebit Margin | -59.3% | -81.4% | -84.9% | -71.4% | -51.4% | |
| Ebitda Margin | -51.4% | -73.6% | -80.2% | -67.9% | -49.2% | |
| Operating Profit Margin | -43.0% | -128.7% | -85.1% | -75.5% | -52.3% | |
| Pretax Profit Margin | -59.3% | -121.6% | -72.9% | -71.6% | -52.5% | |
| Continuous Operations Profit Margin | -59.2% | -121.1% | -72.5% | -71.6% | -52.5% | |
| Net Profit Margin | -65.2% | -121.1% | -72.5% | -71.6% | -52.5% | |
| Bottom Line Profit Margin | -65.2% | -121.1% | -72.5% | -71.6% | -52.5% | |
| Current Ratio | 4.244 | 4.098 | 7.707 | 11.215 | 17.046 | |
| Quick Ratio | 3.862 | 3.455 | 7.045 | 10.564 | 16.512 | |
| Solvency Ratio | -0.694 | -1.504 | -0.907 | -0.615 | -0.459 | |
| Cash Ratio | 3.316 | 1.751 | 5.368 | 9.800 | 15.103 | |
| Price To Earnings Ratio | -5.198 | -1.038 | -9.929 | -7.121 | -32.747 | |
| Price To Earnings Growth Ratio | 0.099 | -0.012 | -1.771 | -0.201 | 0.493 | |
| Forward Price To Earnings Growth Ratio | 0.099 | -0.012 | -1.771 | -0.201 | 0.493 | |
| Price To Earnings Diluted Ratio | -5.585 | -1.038 | -9.929 | -7.121 | -32.747 | |
| Price To Earnings Diluted Growth Ratio | 0.100 | -0.012 | -1.771 | -0.201 | 0.493 | |
| Price To Book Ratio | 1.323 | 0.654 | 2.184 | 1.259 | 3.370 | |
| Price To Sales Ratio | 3.383 | 1.257 | 7.195 | 5.122 | 17.137 | |
| Price To Free Cash Flow Ratio | -7.716 | -2.430 | -13.334 | -10.445 | -24.255 | |
| Price To Operating Cash Flow Ratio | -8.027 | -2.479 | -14.422 | -11.466 | -24.870 | |
| Debt To Assets Ratio | 0.088 | 0.041 | 0.029 | 0.080 | 0.080 | |
| Debt To Equity Ratio | 0.116 | 0.058 | 0.036 | 0.102 | 0.097 | |
| Debt To Capital Ratio | 0.104 | 0.055 | 0.035 | 0.093 | 0.089 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.073 | 0.065 | |
| Financial Leverage Ratio | 1.323 | 1.392 | 1.227 | 1.273 | 1.216 | |
| Working Capital Turnover Ratio | 0.597 | 0.520 | 0.289 | 0.216 | 0.212 | |
| Operating Cash Flow Ratio | -0.695 | -1.203 | -1.111 | -1.089 | -1.960 | |
| Operating Cash Flow Sales Ratio | -0.422 | -0.507 | -0.499 | -0.447 | -0.689 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.040 | 1.020 | 1.082 | 1.098 | 1.025 | |
| Debt Service Coverage Ratio | -1.725 | -23.379 | -18.068 | -246.667 | -42.712 | |
| Interest Coverage Ratio | 0.000 | 0.000 | -212.726 | -274.279 | -45.409 | |
| Short Term Operating Cash Flow Coverage Ratio | -1.418 | -16.218 | -12.430 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.418 | -4.578 | -4.215 | -1.073 | -1.395 | |
| Capital Expenditure Coverage Ratio | -24.804 | -50.244 | -12.254 | -10.235 | -39.460 | |
| Dividend Paid And Capex Coverage Ratio | -24.804 | -50.244 | -12.254 | -10.235 | -39.460 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.251 | -0.856 | -6.117 | -2.233 | -25.053 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 47.7% | ▼-2.5% | ▼-4.1% |
| Ebit Margin | -59.3% | ▲22.1% | ▲10.3% |
| Ebitda Margin | -51.4% | ▲22.2% | ▲13.1% |
| Operating Profit Margin | -43.0% | ▲85.6% | ▲33.9% |
| Pretax Profit Margin | -59.3% | ▲62.2% | ▲16.3% |
| Continuous Operations Profit Margin | -59.2% | ▲61.9% | ▲16.2% |
| Net Profit Margin | -65.2% | ▲55.9% | ▲11.4% |
| Bottom Line Profit Margin | -65.2% | ▲55.9% | ▲11.4% |
| Current Ratio | 4.244 | ▲0.146 | ▼-4.618 |
| Quick Ratio | 3.862 | ▲0.408 | ▼-4.425 |
| Solvency Ratio | -0.694 | ▲0.811 | ▲0.142 |
| Cash Ratio | 3.316 | ▲1.566 | ▼-3.751 |
| Price To Earnings Ratio | -5.198 | ▼-4.160 | ▲6.009 |
| Price To Earnings Growth Ratio | 0.099 | ▲0.111 | ▲0.378 |
| Forward Price To Earnings Growth Ratio | 0.099 | ▲0.111 | ▲0.378 |
| Price To Earnings Diluted Ratio | -5.585 | ▼-4.547 | ▲5.699 |
| Price To Earnings Diluted Growth Ratio | 0.100 | ▲0.112 | ▲0.378 |
| Price To Book Ratio | 1.323 | ▲0.669 | ▼-0.435 |
| Price To Sales Ratio | 3.384 | ▲2.126 | ▼-3.435 |
| Price To Free Cash Flow Ratio | -7.716 | ▼-5.286 | ▲3.920 |
| Price To Operating Cash Flow Ratio | -8.027 | ▼-5.548 | ▲4.226 |
| Debt To Assets Ratio | 0.088 | ▲0.046 | ▲0.024 |
| Debt To Equity Ratio | 0.116 | ▲0.059 | ▲0.034 |
| Debt To Capital Ratio | 0.104 | ▲0.050 | ▲0.029 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.028 |
| Financial Leverage Ratio | 1.323 | ▼-0.069 | ▲0.037 |
| Working Capital Turnover Ratio | 0.597 | ▲0.076 | ▲0.230 |
| Operating Cash Flow Ratio | -0.695 | ▲0.507 | ▲0.516 |
| Operating Cash Flow Sales Ratio | -0.421 | ▲0.086 | ▲0.091 |
| Free Cash Flow Operating Cash Flow Ratio | 1.040 | ▲0.020 | ▼-0.013 |
| Debt Service Coverage Ratio | -1.725 | ▲21.654 | ▲64.785 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲106.483 |
| Short Term Operating Cash Flow Coverage Ratio | -1.418 | ▲14.800 | ▲4.595 |
| Operating Cash Flow Coverage Ratio | -1.418 | ▲3.160 | ▲1.118 |
| Capital Expenditure Coverage Ratio | -24.804 | ▲25.440 | ▲2.595 |
| Dividend Paid And Capex Coverage Ratio | -24.804 | ▲25.440 | ▲2.595 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.251 | ▼-2.395 | ▲4.251 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $190.1M | $75.0M | $361.4M | $240.0M | $723.3M | |
| Enterprise value | $93.9M | $37.5M | $246.3M | $71.1M | $520.0M | |
| EV / Sales | 1.67x | 0.63x | 4.90x | 1.52x | 12.32x | |
| EV / Op. cash flow | -3.96x | -1.24x | -9.83x | -3.40x | -17.88x | |
| EV / Free cash flow | -3.81x | -1.22x | -9.09x | -3.09x | -17.44x | |
| EV / EBITDA | -3.25x | -0.86x | -6.12x | -2.23x | -25.05x | |
| Net debt / EBITDA | 3.33x | 0.85x | 2.86x | 5.31x | 9.79x | |
| Current ratio | 4.24x | 4.10x | 7.71x | 11.21x | 17.05x | |
| Income quality | -1.22x | 0.42x | 0.69x | 0.62x | 1.31x | |
| Graham net-net | $2 | $1 | $4 | $5 | $7 | |
| Tax burden | 109.9% | 99.6% | 99.4% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 149.3% | 85.8% | 100.4% | 102.2% | |
| Working capital | $110.5M | $77.9M | $151.2M | $196.4M | $238.1M | |
| Invested capital | $155.5M | $133.5M | $179.0M | $222.0M | $244.8M | |
| Return on assets | -19.3% | -45.3% | -17.9% | -13.8% | -8.5% | |
| Operating ROA | -13.8% | -42.3% | -19.2% | -14.1% | -10.0% | |
| Return on tangible assets | -23.8% | -63.2% | -19.7% | -15.0% | -8.5% | |
| Return on equity | -25.5% | -63.0% | -22.0% | -17.6% | -10.3% | |
| Return on invested capital | -14.0% | -56.1% | -23.3% | -15.7% | -8.9% | |
| Return on capital employed | -15.5% | -57.1% | -23.7% | -15.8% | -9.0% | |
| Earnings yield | -19.3% | -96.3% | -10.1% | -14.0% | -3.1% | |
| Free cash flow yield | -13.0% | -41.1% | -7.5% | -9.6% | -4.1% | |
| Capex / Op. cash flow | -4.0% | -2.0% | -8.2% | -9.8% | -2.5% | |
| Capex / Depreciation | 24.9% | 12.9% | 85.8% | 126.7% | 79.7% | |
| Capex / Sales | 1.7% | 1.0% | 4.1% | 4.4% | 1.7% | |
| SG&A / Sales | 66.2% | 0.0% | 0.0% | 93.7% | 76.4% | |
| R&D / Sales | 24.6% | 42.8% | 43.6% | 37.4% | 31.0% | |
| Stock comp / Sales | 17.5% | 19.7% | 19.5% | 15.4% | 5.9% | |
| Intangibles / Total assets | 19.2% | 28.4% | 9.0% | 7.6% | 0.0% | |
| Days sales outstanding | 74d | 77d | 65d | 78d | 143d | |
| Days payables outstanding | 105d | 25d | 17d | 24d | 26d | |
| Operating cycle | 235d | 276d | 284d | 297d | 296d | |
| Cash conversion cycle | 130d | 251d | 267d | 273d | 269d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+153.6%EV / Sales ▲+165.3%EV / EBITDA ▼-280.0%EV / Op. cash flow ▼-2.722Earnings yield ▲+0.770
Profitability
Return on equity ▲+0.375Return on assets ▲+0.260Return on invested capital ▲+0.421Return on capital employed ▲+0.416Operating ROA ▲+0.285Income quality ▼-1.634Tax burden ▲+0.103
Efficiency
Days sales outstanding ▼-3.721Days payables outstanding ▲+79.235Operating cycle ▼-41.169Cash conversion cycle ▼-120.405Capex / Sales ▲+0.007R&D / Sales ▼-0.182
Balance-sheet strength
Current ratio ▲+0.146Net debt / EBITDA ▲+2.481Working capital ▲+32589000.000Invested capital ▲+22038000.000Intangibles / Total assets ▼-0.092
Change over 5 years
Valuation
Market cap ▼-73.7%EV / Sales ▼-86.4%EV / EBITDA ▲+87.0%EV / Op. cash flow ▲+13.919Earnings yield ▼-0.162
Profitability
Return on equity ▼-0.152Return on assets ▼-0.108Return on invested capital ▼-0.051Return on capital employed ▼-0.065Operating ROA ▼-0.038Income quality ▼-2.527Tax burden ▲+0.099
Efficiency
Days sales outstanding ▼-69.773Days payables outstanding ▲+78.209Operating cycle ▼-60.828Cash conversion cycle ▼-139.036Capex / Sales -0.000R&D / Sales ▼-0.064
Balance-sheet strength
Current ratio ▼-12.802Net debt / EBITDA ▼-6.457Working capital ▼-127562000.000Invested capital ▼-89306000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-04 BlackRock Inc. Takes $16.91 Million Position in 908 Devices Inc. $MASS BlackRock Inc. acquired a new stake in shares of 908 Devices Inc. (NASDAQ: MASS) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,944,236 shares of the company''s stock, valued at approximately $16,915,000. BlackRock Inc. owned approximately 5.14% of
- 2026-09-01 908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City.908 Devices'' management is scheduled to present at 3:45 p.m. Eastern Time. The presentation is webcast and interested parties can register for th.
- 2026-08-31 908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates 908 Devices (NASDAQ: MASS) outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue. Speaking at the Midwest IDEAS Conference, CEO and Co-Founder Kevin Knopp said the company has spent the past 18 months reshaping its operations around portable tools
- 2026-08-29 908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates 908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.
- 2026-08-21 Is 908 Devices Inc (MASS) Overvalued After 3.3% Rally? GF Value Says Overvalued On August 21, 2026, 908 Devices Inc (MASS) shares rose 3.3% to $10.68, marking a notable increase within its 52-week range of $5.03 to $10.70. The stock has sho
- 2026-08-17 TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection 908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
- 2026-08-15 908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market 908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.
- 2026-08-13 908 Devices Q2: Another Solid Report 908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%. Management raised 2026 revenue guidance to $68–$70 million, implying 21–25% growth, while operating and net losses narrowed.
- 2026-08-12 908 Devices: Mission Critical Devices Drive Growth 908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M.
- 2026-08-12 908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 17th Annual Midwest IDEAS Conference on Wednesday, August 26, 2026. The Company presentation is scheduled to begin at 9:55 a.m. CT / 10:55 a.m. ET. The presentation is.